Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
adaptable, added, adding, aggressive, Aliqopa, antiangiogenic, antibody, antitumor, apparent, ASCO, ATM, auditor, Automated, beating, bill, biology, blended, block, body, broader, capable, Casulo, CDK, certainty, Combinatorial, confer, consult, conventional, copanlisib, corroborated, counsel, cytogenetic, David, diarrhea, diffuse, directionally, directly, disagree, DLBCL, Durable, elevated, elusive, emerging, emphasize, evading, exit, expeditiously, faster, FDAreview, FL, flat, hand, head, Hedging, highest, idealelisib, ifat, immunochemotherapy, importantly, incremental, indefinitely, indirectly, infrequent, intermittent, interruption, intractable, issuedASU, JCO, jointly, justified, leukemic, leverage, leveraging, line, long, master, maximize, meaningfully, minimize, multicenter, MYC, Narrow, Notwithstanding, offshore, oncogene, orderly, overcoming, Overview, owed, partner, partnership, PCAOB, percent, PET, plasticity, poor, potency, predefined, preferential, Presage, presence, president, pressure, prioritize, prolonged, put, qualification, quantity, quickly, rash, recovered, recurring, relapsed, repatriated, rescind, Rescission, resource, resume, revalue, revalued, Rituxan, rituximab, run, safer, saline, scan, settle, SLL, spread, struggle, Subpart, subset, suppression, taxation, thereof, top, transformation, translation, undergoing, unobservable, uptake, urge, Urso, validate, Venclexta, venetoclax, vice, vitro, voruciclib, withheld
Removed:
accrue, ASH, combining, consolidated, Daniel, deficit, disability, distinct, distributed, dollar, doubt, Dr, ending, Gold, growing, heavily, Ib, idelalisib, interfering, invoiced, minimum, myelosuppresion, ofCancer, ovarian, phosphatidylinositide, plasma, preclinical, purpose, receptor, Rule, separation, stem, subsidiary, supporting, underwritten
Filing tables
Filing exhibits
Associated MEIP transcripts
MEIP similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
MEI Pharma, Inc.
San Diego, CA
We hereby consent to the incorporation by reference in the Registration Statements on Form S -3 (File Nos.333-225-465,333-217645,333-186070,333-184011,333-174789,333-146453, and333-136440) and Form S -8 (File Nos.333-216103,333-213278,333-201703,333-179591,333-174790,333-169719, and333-156985) of MEI Pharma, Inc. of our reports dated August 29, 2018, relating to the financial statements and the effectiveness of MEI Pharma, Inc.’s internal control over financial reporting, which appear in this Form10-K.
/s/ BDO USA, LLP
San Diego, California
August 29, 2018